Analysis of life-long strategies to prevent Pneumocystis carinii pneumonia in patients with variable HIV progression rates

AIDS

Volumn 12, Issue 11, 1998, Pages 1317-1325

  Wynia, Matthew K ^a,b   Ioannidis, John P A ^a   Lau, Joseph ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b AMERICAN MEDICAL ASSOCIATION   (United States)

Author keywords

Models; Opportunistic infections; Pneumocystis carinii pneumonia; Prophylaxis

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DAPSONE; PENTAMIDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DRUG COST; DRUG EFFICACY; DRUG TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SURVIVAL;

EID: 0032581695     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199811000-00013     Document Type: Article

References (47)

1. Gallant JE, Moore RD, Chaisson RE: Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 1994, 120:932-944.
2. Osmond D, Charlebois E, Lang W, Shiboski S, Moss A: Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993. JAMA 1994, 271:1083-1087.
3. Moore RD, Keruly, JC, Chaisson, RE: Effectiveness of combination antiretroviral therapy in clinical practice. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 1997 [abstract 1-176].
4. Bozette SA, Finkelstein DM, Spector SA, et al.: A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995, 332:693-699.
5. Powderly WG: Prophylaxis for HIV-related infections: a work in progress. Ann Intern Med 1996, 124:342-344.
6. Ioannidis JPA, Cappelleri JC, Skolnik PR, Lau J, Sacks HS: A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996, 156:177-188.
7. Walmsley S, Levinton C, Brunton J, et al.: A multicenter randomized double-blind placebo-controlled trial of adjunctive corticosteroids in the treatment of Pneumocystis carinii pneumonia complicating the acquired immune deficiency syndrome. J Acquir Immune Defic Syndr Hum Retrovir 1995, 8:348-357.
8. Clumek N: Primary prophylaxis against opportunistic infections in patients with AIDS. N Engl J Med 1995, 332:739-740.
9. Fischl M, Dickinson G, La Voie L: Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988, 259:1185-1189.
10. Leoung GS, Feigal Jr DW, Montgomery AB, et al.: Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco Community Prophylaxis trial. N Engl J Med 1990, 323:769-775.
11. Hirschel B, Lazzarin A, Chopard P, et al.: A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med 1991, 324:1079-1083.
12. Hardy WD, Feinberg J, Finkelstein DM, et al.: A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med 1992, 327:1842-1848.
13. Martin MA, Cox PH, Beck K, Styer CM, Beall GN: A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Arch Intern Med 1992, 152:523-528.
14. Girard P, Landman R, Gaudebout C, et al.: Dapsonepyrimethamine compared to aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. N Engl J Med 1993, 328:1514-1520.
15. Hughes W, Leoung G, Kramer F, et al.: Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993, 328:1521-1527.
16. May T, Beuscart C, Reynes J, et al.: Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical trial. LFPMI Study Group. Ligue Francaise de Prevention des Maladies Infectieuses. J Acquir Immune Defic Syndr 1994, 7:457-462.
17. Bozette SA, Forthal D, Sattler FR, et al.: The tolerance for zidovudine plus thrice weekly or daily trimethoprim-sulfamethoxazole with and without leucovorin for primary prophylaxis in advanced HIV disease. Am J Med 1995, 98:177-182.
18. US Public Health Service/Infectious Diseases Society of America: 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Ann Intern Med 1997, 127:922-946.
19. 3: a cost-effectiveness analysis. J Acquir Immune Defic Syndr 1991, 4:521-531.
20. Castellano AR, Nettleman MD: Cost and benefit of secondary prophylaxis for Pneumocystis carinii pneumonia. JAMA 1991, 266:820-824.
21. Freedberg KA, Hardy WD, Holzman RS, Tosteson AN, Craven DE: Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients. Med Decis Making 1996, 16:29-35.
22. Bayard PJ, Berger TG, Jacobson MA: Drug hypersensitivity reactions and human immunodeficiency virus disease. J Acquir Immune Defic Syndr 1992, 5:1237-1257.
23. Gluckstein D, Ruskin J. Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ. Clin Infect Dis 1995, 20:849-853.
24. Jung AC, Paauw DS: Management of adverse reactions to trimethoprim-sulfamethoxazole in human immunodeficiency virus-infected patients. Arch Intern Med 1994, 154:2402-2406.
25. Nguyen M-T, Weiss PJ, Wallace MR: Two-day oral desensitization to trimethoprim-sulfamethoxazole in HIV-infected patients. AIDS 1995, 9:573-575.
26. Saah AJ, Hoover DR, Peng Y, et al.: Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study. JAMA 1995, 273:1197-1202.
27. Masur H, Ognibene FP, Yarchoan R, et al.: CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 1989, 111:223-231.
28. Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A: The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 1490, 322:161-165.
29. Carr A, Swanson C, Penny R, Cooper DA: Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocysits carinii pneumonia and AIDS. J Infect Dis 1993, 167:180-185.
30. Dolan MJ, Clerici M, Blatt SP, et al.: In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis 1995, 172:79-87.
31. Chin DP, Reingold AL, Stone EN, et al.: The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients - a prospective study. J Infect Dis 1994, 170:578-584.
32. Mellors JW, Rinaldo Jr CR, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
33. O'Brien W, Hartigan PM, Martin D, et al.: Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med 1996, 334:426-431.
34. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
35. Carpenter CCJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA Panel. JAMA 1997, 77:1962-1969.
36. Sonnenberg FA, Beck JR: Markov models in medical decision making: a practical guide. Med Decis Making 1993, 13:322-338.
37. Chaisson RE, Keruly J, Richman DD, Moore RD: Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group. Arch Intern Med 1992, 152:2009-2013.
38. Albert JM, Ioannidis JPA, Reichelderfer P, et al.: Statistical issues for HIV surrogate endpoints: point/counterpoint. Stat Med (in press).
39. O'Brien TR, Blattner WA, Waters D, et al.: Serum HIV-1 RNA levels and time to development of AIDS in the multicenter hemophilia cohort study. JAMA 1996, 276:105-110.
40. Saab AJ, Hoover DR, He Y, Kingsley LA, Phair JP: Factors influencing survival after AIDS: report from the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 1994, 7:287-295.
41. The Clinical Cost Manager. Boston: Transition Systems Inc.
42. Finkelstein DM, Williams PL, Molenberghs C, et al.: Patterns of opportunistic infections in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 12:38-45.
43. Mellors JW, Munoz A, Giorgi JV, et al.: Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.
44. Marschner IC, Collier AC, Coombs RW, et al.: Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998, 177:40-47.
45. Katenstein DA, Hammer SM, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996, 335:1091-1098.
46. El-Sadr W, Luskin-Hawk R, Pulling C, et al.: Daily versus thrice weekly trimethoprim-sulfamethoxazole in the prevention of Pneumocystis carinii pneumonia. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 1997 [abstract 1-146].
47. Schneider MME, Borleffs JCC, Jaspers CAJJ, Hoepelman IM: Discontinuation of Pneumocystis carinii pneumonia prophylaxis in HIV infected patients with an increase of their CD4 cell counts (>200/microliter) due to aggressive antiretroviral therapy. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 1997 [abstract LB-11].